Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vicarious Surgical Inc. filings document the company's robotic surgery business, capital structure, governance actions, and public-market status. Recent 8-K reports cover operating results, financial condition, executive employment agreement amendments, and NYSE delisting proceedings for the company's Class A common stock, which is quoted on the OTC market under RBOT.
Proxy and shareholder-vote filings describe amendments to the certificate of incorporation related to a reverse stock split authorization and the voting mechanics of the company's Class A and Class B common stock. Form 25 and related reports document removal of the Class A common stock from NYSE listing and registration under Section 12(b).
Vicarious Surgical Inc. is having its warrants removed from listing and registration on the New York Stock Exchange under Section 12(b) of the Securities Exchange Act of 1934. The notification is made on SEC Form 25, with the Exchange certifying it has reasonable grounds to file.
The affected security is described as warrants, with each whole warrant exercisable for 1/30th of a share of Class A common stock at an exercise price of $345.00. The New York Stock Exchange states it has complied with its rules to strike this class of securities, and that the issuer has complied with exchange and SEC requirements for the voluntary withdrawal of this class from listing and registration.
Vicarious Surgical Inc. entered into an at-the-market offering agreement with H.C. Wainwright & Co., allowing the company to sell shares of its Class A common stock from time to time through the sales agent, subject to a new Form S-3 shelf registration statement becoming effective. The ATM prospectus supplement currently permits sales of shares with an aggregate market value of $2,286,052, based on the limitations of General Instruction I.B.6 of Form S-3.
The company will pay Wainwright a 3.0% commission on gross proceeds, plus specified fees and expenses, and can set parameters such as timing, daily limits, and minimum prices for any share sales. Separately, the NYSE has begun proceedings to delist and has immediately suspended trading in Vicarious Surgical’s publicly traded warrants (symbol “RBOT.WS”) due to “abnormally low” trading price levels, and the company does not intend to appeal. The Class A common stock will continue trading on the NYSE under “RBOT,” but its continued listing depends on regaining compliance with NYSE Section 802.01B by October 10, 2026. The company also issued a press release announcing guidance for anticipated cash burn for fiscal year 2026.
Vicarious Surgical Inc. has called a special stockholder meeting on January 9, 2026 to vote on allowing the exercise of Common Warrants issued on October 7, 2025. These warrants give an institutional investor the right to buy up to 2,300,000 shares of Class A common stock at an exercise price of $5.10 per share, but they are not exercisable until stockholders approve their exercise under New York Stock Exchange rules.
The company previously raised about $5.9 million in gross proceeds in an October 2025 registered direct offering and concurrent private placement. As of September 30, 2025, it held roughly $3.2 million in cash and $10.3 million in short‑term investments. If the proposal is approved and all warrants are exercised for cash, Vicarious Surgical could receive up to approximately $11.7 million in additional gross proceeds, while existing holders would face dilution as up to 2,300,000 new shares become issuable. The board of directors unanimously recommends voting “FOR” the proposal.
Vicarious Surgical Inc. has filed a shelf registration statement allowing it to offer up to $100,000,000 of Class A common stock, preferred stock, debt securities, warrants, rights and units over time. A separate sales agreement prospectus covers an at-the-market program for up to $3,000,000 of Class A common stock through H.C. Wainwright & Co., which is included within the $100 million capacity.
The company develops a next-generation single-port robotic surgical system that has not yet been authorized by the FDA; it targets a clinical-ready system by mid‑2026, design freeze by the end of 2026, and first‑in‑human trials in 2027, subject to regulatory clearance. Net proceeds from any future sales may be used for general corporate purposes such as working capital, capital expenditures, research and development, and potential acquisitions. Vicarious Surgical also discloses an NYSE compliance plan after falling below the $50 million minimum market capitalization and warns that failure to regain compliance within the 18‑month cure period could lead to suspension and delisting.
Vicarious Surgical Inc. is registering for resale up to 2,300,000 shares of Class A common stock issuable from Series A and Series B common warrants held by a single selling stockholder. The company is not offering any shares in this prospectus and will only receive cash if these $5.10 warrants are exercised for cash.
Class A common stock outstanding was 6,126,891 shares as of December 4, 2025, and would be 8,194,273 shares assuming full warrant exercise, illustrating the potential dilution if all warrants are exercised. The selling holder may sell shares over time in public or private transactions at market or negotiated prices.
Vicarious Surgical is developing a next-generation single-port robotic system for soft tissue surgery, which has not yet received FDA authorization. The company completed two controlled builds of its platform in 2025, targets a clinical-ready system by mid-2026 and first-in-human trials in 2027, and is operating under an NYSE compliance plan after previously falling below a $50 million market capitalization standard.
Vicarious Surgical Inc. is asking stockholders to approve the exercise of Common Warrants to purchase up to 2,300,000 shares of Class A common stock. These Series A and Series B Common Warrants, issued on October 7, 2025 with a cash exercise price of $5.10 per share and a five-year term starting on stockholder approval, were part of a registered direct offering and concurrent private placement that raised about $5.9 million in gross proceeds. If fully exercised for cash at the initial price, the warrants could bring in up to approximately $11.7 million in additional gross proceeds.
The approval is required under NYSE Rule 312.03(c) because the warrants cover more than 20% of the company’s outstanding common stock at a price below the NYSE “Minimum Price.” The company notes that it had cash and cash equivalents of about $3.2 million and short-term investments of about $10.3 million as of September 30, 2025, and views the potential proceeds as important to funding operations. If the proposal is approved and the warrants are exercised, existing holders would be diluted by the issuance of 2,300,000 additional Class A shares, and future sales of these shares could pressure the stock price.
Vicarious Surgical Inc. reported an insider share sale by a senior executive. On 12/03/2025, a reporting person who serves as Director, President and a 10% owner sold 463 shares of Class A common stock at a weighted average price of $2.952 per share. After this transaction, the insider directly beneficially owns 47,885 shares.
The company explains that the sale was executed solely to cover tax withholding obligations arising from the vesting of restricted stock units granted on June 2, 2023, under its equity incentive plan. The transaction was a mandatory “sell to cover” arrangement rather than a discretionary trade by the insider, and involved multiple trades at prices ranging from $2.715 to $3.34 per share.
Vicarious Surgical Inc. insider transaction: A reporting person who is a director, chief technology officer and 10% owner of Vicarious Surgical Inc. (RBOT) reported a small sale of Class A common stock. On 12/03/2025, the insider sold 239 shares of Class A common stock at a weighted average price of $2.97 per share, with individual trades ranging from $2.725 to $3.34 per share. After this transaction, the insider beneficially owns 33,623 shares directly. The sale was executed to cover tax withholding obligations arising from the vesting of restricted stock units granted on June 2, 2023, under the company’s equity incentive plan and is described as a mandatory "sell to cover" rather than a discretionary trade.
Vicarious Surgical Inc. insider Sammy Khalifa filed a Form 144 notice to sell 239 shares of Class A common stock through UBS Financial Services on the NYSE, with an aggregate market value of 619.01.
The shares relate to restricted stock that lapsed and was acquired on 12/02/2025, in a total amount of 696 shares. The notice reports that Class A common stock shares outstanding were 5,894,273. Over the prior three months, Khalifa reported additional sales of 239 and 653 Class A shares, with gross proceeds of 1293 and 1696, respectively.
Vicarious Surgical Inc. reported governance changes as two directors, Beverly Huss and Randy Clark, resigned from its Board of Directors effective December 1, 2025. The company stated their resignations were part of a Board decision to reduce its size and were not due to any disagreement over operations, policies, or practices.
Following these departures, the Board was reduced from nine members to seven. To fill committee roles, Joseph Doherty joined the Audit Committee, Fuad Ahmad joined the Compensation Committee, and Victoria Carr‑Brendel was named Chair of the Compensation Committee, all effective the same day.
On December 3, 2025, Vicarious Surgical also announced via press release that it had updated guidance on its 2025 cash burn and highlighted the committee changes. This press release was furnished as an exhibit and not deemed filed for liability purposes under securities laws.